Reference : L'etude clinique du mois. L'etude FLAME dans la broncho-pneumopathie chronique obstru...
Scientific journals : Article
Human health sciences : Cardiovascular & respiratory systems
L'etude clinique du mois. L'etude FLAME dans la broncho-pneumopathie chronique obstructive.
[en] Study of the month : FLAME study in chronic obstructive pulmonary disease
Corhay, Jean-Louis mailto [Université de Liège - ULiège > Département des sciences cliniques > Département des sciences cliniques >]
Revue Médicale de Liège
Yes (verified by ORBi)
[en] Administration, Inhalation ; Aged ; Bronchodilator Agents/administration & dosage/adverse effects ; Female ; Fluticasone/administration & dosage/adverse effects ; Forced Expiratory Volume/drug effects ; Glycopyrrolate/administration & dosage/adverse effects ; Humans ; Indans/administration & dosage/adverse effects ; Male ; Middle Aged ; Pulmonary Disease, Chronic Obstructive/drug therapy/physiopathology ; Quinolones/administration & dosage/adverse effects ; Salmeterol Xinafoate/administration & dosage/adverse effects ; Treatment Outcome ; Bronchodilators ; Chronic obstructive pulmonary disease ; Exacerbations ; Inhaled corticosteroids
[en] The place of combinations of bronchodilators (longacting beta-agonist / muscarinic agonist or LABA / LAMA) in the prevention of the exacerbations of the chronic obstructive pulmonary disease (COPD) is not still clearly established, and need a comparison with combination of LABA/ inhaled steroids. FLAME was a randomized non-inferiority phase 3 study comparing indacaterol/glycopyrronium 110/50 mug (IND/GLY) once daily with salmeterol/proprionate of fluticasone 50/500 mug (SAL/FC) twice daily. The primary objective of the study was to demonstrate that IND/GLY was non-inferior to SAL/FC in terms of reduction of all COPD exacerbations (mild/moderate/severe) during 52 weeks of treatment in patients having had at least 1 exacerbation in previous 12 months. The combination IND/GLY showed not only non inferiority, but also superiority, to SAL/FC in reducing the annual rate of all COPD exacerbations (mild, moderate, or severe) by 11 % by comparison with SAL/FC (p = 0.003), and by 17 % for the annual rate of moderate or severe exacerbations (p inferior to 0.001). IND/GLY prolonged the time to the first COPD exacerbation by 16 % for mild, 22 % for moderate and 19 % for severe by comparison with SAL/FC (all with p inferior to 0.05). FLAME study showed that IND/GLY, a steroid-free option, is more effective than SAL/FC in preventing COPD exacerbations in patients with one or more exacerbations in the past year.

File(s) associated to this reference

Fulltext file(s):

Open access
CORHAY 2016_Etude FLAME_RMLg_ppediteur.pdfPublisher postprint461.77 kBView/Open

Bookmark and Share SFX Query

All documents in ORBi are protected by a user license.